Table 3.
Characteristics of sudden sensorineural hearing loss cases.
| Characteristics | Tozinameran | Elasomeran | ||||||||||||
|
|
<21 days (n=108, 76.1%) | >21 days (n=34, 23.9%) | Total (n=142) | <21 days (n=26, 86.7%) | >21 days (n=3, 10.3%) | Total (n=29) | ||||||||
| Sex, n (%) | ||||||||||||||
|
|
Male | 43 (39.8) | 15 (44.1) | 58 (40.8) | 13 (50) | 1 (33.3) | 14 (48.3) | |||||||
|
|
Female | 65 (60.2) | 19 (55.9) | 84 (59.2) | 13 (50) | 2 (66.7) | 15 (51.7) | |||||||
| Age (years) | ||||||||||||||
|
|
Values, median (range) | 50 (13-83) | 51 (16-72) | 51 (13-83) | 51 (33-81) | 43 (36-68) | 47 (33-81) | |||||||
|
|
0-18, n (%) | 3 (2.8) | 1 (2.9) | 4 (2.8) | 0 (0) | 0 (0) | 0 (0) | |||||||
|
|
19-29, n (%) | 7 (6.5) | 0 (0) | 7 (4.9) | 0 (0) | 0 (0) | 0 (0) | |||||||
|
|
30-49, n (%) | 43 (39.8) | 12 (35.3) | 55 (38.7) | 10 (38.5) | 2 (66.7) | 12 (41.4) | |||||||
|
|
50-64, n (%) | 26 (24.1) | 17 (50) | 43 (30.3) | 9 (34.6) | 0 (0) | 9 (31) | |||||||
|
|
65-74, n (%) | 19 (17.6) | 4 (11.8) | 23 (16.2) | 6 (23.1) | 1 (33.3) | 7 (24.1) | |||||||
|
|
≥75, n (%) | 10 (9.3) | 0 (0) | 10 (7) | 1 (3.8) | 0 (0) | 1 (3.4) | |||||||
| Medical history, n (%) | 38 (35.2) | 12 (35.3) | 50 (35.2) | 7 (26.9) | 2 (66.7) | 9 (31) | ||||||||
|
|
CVa | 9 (8.3) | 5 (14.7) | 14 (9.9) | 2 (7.7) | 1 (33.3) | 3 (10.3) | |||||||
|
|
ONb | 12 (11.1) | 5 (14.7) | 17 (12) | 3 (11.5) | 1 (33.3) | 4 (13.8) | |||||||
|
|
AIMc | 7 (6.5) | 2 (5.9) | 9 (6.3) | 0 (0) | 0 (0) | 0 (0) | |||||||
|
|
CV and ON | 4 (3.7) | 0 (0) | 4 (2.8) | 0 (0) | 0 (0) | 0 (0) | |||||||
|
|
ON and AIM | 3 (2.8) | 0 (0) | 3 (2.1) | 1 (3.8) | 0 (0) | 1 (3.4) | |||||||
|
|
Other etiologies | 3 (2.8) | 0 | 3 (2.1) | 1 (3.8) | 0 (0) | 1 (3.4) | |||||||
| Time to onsetd (days), median (IQR) | 4 (2-9) | 41 (25-67) | N/Ae | 8 (1-21) | 50 (26-144) | N/A | ||||||||
| Vaccination rank, n (%) | ||||||||||||||
|
|
First dose | 47 (43.5) | 13 (38.2) | 60 (42.2) | 12 (46.2) | 1 (33.3) | 13 (44.8) | |||||||
|
|
Second dose | 39 (36.1) | 14 (41.2) | 53 (37.3) | 10 (38.5) | 2 (66.7) | 12 (41.4) | |||||||
|
|
Booster | 12 (11.1) | 0 (0) | 12 (8.5) | 2 (7.7) | 0 (0) | 2 (6.9) | |||||||
|
|
Unknown | 10 (9.3) | 7 (20.6) | 17 (12) | 2 (7.7) | 0 (0) | 2 (6.9) | |||||||
| Oral steroid administration, n (%) | 48 (44.4) | 19 (55.9) | 67 (47.2) | 14 (53.8) | 2 (66.7) | 16 (55.2) | ||||||||
| Laterality, n (%) | ||||||||||||||
|
|
Unilateral | 94 (87) | 30 (88.2) | 124 (87.3) | 20 (76.9) | 2 (66.7) | 22 (75.9) | |||||||
|
|
Bilateral | 14 (13) | 4 (11.8) | 18 (12.7) | 6 (23.1) | 1 (33.3) | 7 (24.1) | |||||||
| Hearing loss grades, n (%) | ||||||||||||||
|
|
Grade 1 | 22 (20.4) | 2 (5.9) | 24 (16.9) | 4 (15.4) | 3 (100) | 7 (24.1) | |||||||
|
|
Grade 2 | 27 (25) | 10 (29.4) | 37 (26.1) | 5 (19.2) | 0 (0) | 5 (17.2) | |||||||
|
|
Grade 3 | 35 (32.4) | 11 (32.4) | 46 (32.4) | 7 (26.9) | 0 (0) | 7 (24.1) | |||||||
|
|
Grade 4 | 13 (12) | 6 (17.6) | 19 (13.4) | 3 (11.5) | 0 (0) | 3 (10.3) | |||||||
|
|
Grade 5 | 11 (10.2) | 5 (14.7) | 16 (11.3) | 7 (26.9) | 0 (0) | 7 (24.1) | |||||||
| Associated cochleovestibular disorders, n (%) | ||||||||||||||
|
|
Tinnitus | 59 (54.6) | 16 (47.1) | 75 (52.8) | 8 (30.8) | 2 (66.7) | 10 (34.5) | |||||||
|
|
Vertigo and balance disorders | 33 (30.6) | 8 (23.5) | 41 (28.9) | 11 (42.3) | 1 (33.3) | 12 (41.4) | |||||||
| Time to recovery (days), median (range) | 15 (5-67.5) | 11 (8-22.5) | N/A | 21 (2-90) | NDf | N/A | ||||||||
| Positive rechallenge, n (%) | 5 (4.6) | 0 (0) | 5 (3.5) | 2 (7.7) | 1 (33.3) | 3 (10.3) | ||||||||
aCV: cardiovascular.
bON: otoneurological.
cAIM: autoimmune disease.
dInterval between vaccine administration and symptom onset.
eN/A: not applicable.
fND: not determined.